On June 15, 2026, the National Institutes of Health (NIH) announced that moving forward, NICEATM will continue its important work as a division of the newly created NIH Office of Research Innovation, Validation, and Application (ORIVA). Soon, NICEATM content that you see on this webpage will be transitioned to the NIH ORIVA webpage. In the meantime, you can learn more about the new office and how it is structured.

https://ntp.niehs.nih.gov/go/iccvamforum-2026

ICCVAM Public Forum: July 2026

Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM): advancing alternatives to animal testing

July 29-30, 2026

NIH Neuroscience Center Building, 6001 Executive Blvd., Rockville, MD

Agenda (July 27 - revised final draft)

Slides presented at the meeting and videos from the meeting are available below. 

ICCVAM’s goals include promotion of national and international partnerships between governmental and nongovernmental groups, including academia, industry, advocacy groups, and other key stakeholders. To foster these partnerships ICCVAM holds annual public forums to share information and facilitate direct communication of ideas and suggestions from stakeholders.

At this meeting, representatives of ICCVAM member agencies described their agencies' activities both to advance new approaches to safety testing of chemicals and medical products and to reduce the amount of testing required. In-person and remote participants asked clarifying or follow-up questions of the ICCVAM members about their presentations during the meeting. Stakeholders also presented public statements on ICCVAM activities. 

Presentations

Overview of the Office of Research Innovation, Validation, and Application (ORIVA)
Warren Casey, ORIVA, National Institutes of Health (NIH) Office of the Director, Division of Program Coordination, Planning, and Strategic Initiatives

Complement-ARIE Overview
Margaret Ochocinska, NIH Office of the Director

Accelerating NAMs for Regulatory Readiness Through the FNIH Validation and Qualification Network of Public Private Partnerships
Stacey Adam, Foundation for the NIH

Advancing Drug Discovery for Fibrotic Diseases Using 3D Tissue Models: 3D-MOFIB TDC
Marc Ferrer, National Center for Advancing Translational Sciences

NICEATM Update
Helena Hogberg, ORIVA Division of NICEATM

Outcomes of OECD WNT-38 Meeting
Karissa Kovner, Senior Advisor for International Affairs, Office of Chemical Safety and Pollution Prevention (OCSPP), U.S. Environmental Protection Agency (EPA)

ICCVAM Workgroup Updates
Emily Reinke, General Dynamics Information Technology, contractor supporting ORIVA

Development and Evaluation of Ecological High-throughput Transcriptomics as a NAM for Chronic Ecological Safety Evaluations
Dan Villeneuve, OCSPP, EPA

New Approach Methodologies: An FDA Perspective
Steven Kozlowski, U.S. Food and Drug Administration (FDA)

Systematic Review Workflow Can Already Incorporate NAMs in Evidence Syntheses
Andrew Rooney, National Institute of Environmental Health Sciences (NIEHS)

NAMs as a Mechanistic Bridge Along the Exposure-to-outcome Continuum
David Reif, NIEHS

NICEATM Computational Efforts Updates
Kamel Mansouri, ORIVA Division of NICEATM

AFMC/AFRL Activities in NAMs
Krysten Jones, U.S. Air Force Materiel Command

Public Comments